About Us

At Nanomedical Diagnostics, our goal is to help you fully characterize and explore your biomolecules to make better decisions earlier. We have developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that makes label-free kinetic binding and affinity data accessible to all researchers. Unique graphene biosensors at the heart of the assay deliver highly-sensitive kinetic characterization of small molecules ≥10 Da in complex samples from solvents and detergents to cell fractions and tissue lysate. With an unprecedented 11-log dynamic range and the ability to detect with a minuscule amount of sample, the platform is a unique orthogonal technology to accelerate drug discovery.

As the world’s leading mass-manufacturer of next-generation graphene biosensors, our mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms. Our next system, Agile R200, will support over 20,000 measurements an hour when implemented with a 1536-well plate design configuration and combined with standard automated liquid handlers. It will provide kinetic characterization in an initial high-throughput screen, and is slated to launch early 2019.

 About Us

At Nanomedical Diagnostics, our goal is to help you fully characterize and explore your biomolecules to make better decisions earlier. We have developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that makes label-free kinetic binding and affinity data accessible to all researchers. Unique graphene biosensors at the heart of the assay deliver highly-sensitive kinetic characterization of small molecules ≥10 Da in complex samples from solvents and detergents to cell fractions and tissue lysate. With an unprecedented 11-log dynamic range and the ability to detect with a minuscule amount of sample, the platform is a unique orthogonal technology to accelerate drug discovery.

As the world’s leading mass-manufacturer of next-generation graphene biosensors, our mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms. Our next system, Agile R200, will support over 20,000 measurements an hour when implemented with a 1536-well plate design configuration and combined with standard automated liquid handlers. It will provide kinetic characterization in an initial high-throughput screen, and is slated to launch early 2019.